Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication

Executive Summary

Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications

You may also be interested in...



Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol

With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients

Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy

Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics

Bristol Is Confident In Abilify Acceptance By Physicians For Depression

Acceptance of Bristol-Myers Squibb's Abilify (aripiprazole) as adjunctive therapy for major depressive disorder may be eased by existing off-label use of the atypical antipsychotic in that market, according to the company

Related Content

UsernamePublicRestriction

Register

PS048931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel